News

DoH to change GP contract to cut correction factors

18-Jul-08

Dr Laurence Buckman
The DoH will change the contract to allow correction factors to be cut legally, the GPC announced yesterday.

The DoH is required to launch a consultation before it unilaterally changes the contract, which the BMA is responding to.

GPC negotiators say the DoH has acknowledged that the Doctors’ and Dentists’ Review Body’s recommendation to cut correction factors is illegal, so is now consulting on how to implement it legally.

The cuts to correction factors mean despite a 2.7 per cent increase to the global sum, all practices on MPIG will effectively receive nothing.

GPC deputy chairman Dr Richard Vautrey said this would mean changing the statement of financial entitlement (SFE) annex of the contract.

‘We will be challenging this in our response which is currently in the hands of our lawyers,’ he said.

GPC chairman Dr Laurence Buckman said after the consultation, a set of instructions will be sent to parliament and practices and legislative changes will be made.

The GPC’s only victory has been that changes will not be back-dated to April, but will come into force when the consultation concludes.

A DoH spokesman said the consultation would close in September. A decision will be taken then based on the comment received. 

tom.ireland@haymarket.com

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Jobs

 

Job of the Week

Latest Clinical Articles

Clincal Review: Gout

Contributed by Dr Richard Stevens, consultant rheumatologist, Buckinghamshire Hospitals. Read more

Altitude-related illness

Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more

Clinical Review - Subfertility in women

Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more

Show all clinical articles

MIMS Product News

Relistor

New drug - Relistor

Wyeth has launched Relistor (methylnaltrexone bromide) for the treatment of opioid-induced constipat... Read more

Thalidomide available in the UK

Thalidomide, under the name of Thalidomide Pharmion is now commercially available in the UK. Read more

MMR catch-up programme

The DoH has written to healthcare professionals to call for urgent action to help reduce the risk of... Read more